Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

MAINtenance of Remission Using RITuximab in Systemic ANCA-associated Vasculitis II

Next Previous
Trial Profile

MAINtenance of Remission Using RITuximab in Systemic ANCA-associated Vasculitis II

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 07 Nov 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rituximab (Primary) ; Cotrimoxazole
  • Indications Anti-neutrophil cytoplasmic antibody-associated vasculitis; Granulomatosis with polyangiitis; Microscopic polyangiitis
  • Focus Therapeutic Use
  • Acronyms MAINRITSAN 2

    • Most Recent Events

    • 02 Nov 2023 Results of pooled analysis from MAINRITSAN, MAINRITSAN 2 and MAINRITSAN 3, published in the Annals of the Rheumatic Diseases
    • 03 May 2023 Results (n=135) of ancillary study of the MAINRITSAN 2 trial exploring the relationship between rituximab plasma concentration, genetic polymorphisms in PK/PD candidate genes, and clinical outcomes, published in the Arthritis and Rheumatology
    • 14 Nov 2022 Results of pooled analysis assessing long term outcome using data from MAINRITSAN trials, presented at the ACR Convergence 2022.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top